NCT02839915
Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 26 versions: 26 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 19 words Show 4 more changesShow less
- Study completion pushed from Jul 31, 2026 to Jan 31, 2027
- Secondary endpoints: details revised at 1 of 1 entry
- Site details revised at 1 of 4 sites
- Publications: details revised at 5 of 5 entries
- Minor Study completion date: Dec 2025 to Jul 31, 2026v25
- Minor Study completion date: Jan 2025 to Dec 2025v24
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 134 to confirmed 56
- Primary completion date changed from estimate of Jan 2025 to Apr 15, 2024
- Site details revised at 4 of 4 sites
Notable Lead sponsor: Rossignol Medical Center to Southwest Autism Research & Resource Centerv22 Show 5 more changesShow less
- Trial status: Active, Not Recruiting to Recruiting
- Primary and study completion dates pushed to Jan 2025
- Eligibility criteria revised
- Site details revised at 4 of 4 sites
- Collaborators: 5 to 4
Show 20 earlier versionsHide 20 earlier versions
- Notable Trial status: Suspended to Active, Not Recruitingv21
- Minor Study sites: 3 to 4
- Collaborators: 6 to 5
Stopped Trial status: Recruiting to Suspended Sponsor's reason: Temporary Clinical Hold / Changing Clinical Sitesv19 Show 5 more changesShow less
- Lead sponsor: Phoenix Children's Hospital to Rossignol Medical Center
- Eligibility criteria revised
- Study sites: 4 to 3
- Study description revised
- Collaborators: 4 to 6
- Minor Study sites: 3 to 4v18
- Minor Primary endpoints revised (2)v17
Notable Lead sponsor: Emory University to Phoenix Children's Hospitalv16 Show 8 more changesShow less
- Primary completion date: Jul 2022 to Jul 1, 2023
- Eligibility criteria expanded, about 73 words
- Enrollment target: 162 to 134
- Study completion date: Jul 2023 to Jul 1, 2024
- Secondary endpoints: 4 to 1
- Study description revised
- Site details revised at 3 of 3 sites
- Collaborators: 3 to 4
Notable Trial status: Not Yet Recruiting to Recruitingv15 Show 4 more changesShow less
- Primary completion date: Jun 2022 to Jul 2022
- Study completion date: Jun 2023 to Jul 2023
- Start date changed from estimate of Jun 2020 to Aug 13, 2020
- Site details revised at 3 of 3 sites
Notable Start date: Oct 2019 to Jun 2020v14 Show 4 more changesShow less
- Eligibility criteria expanded, about 49 words
- Primary endpoints: 1 to 2
- Primary completion date: Jan 1, 2022 to Jun 2022
- Study completion date: Jan 1, 2023 to Jun 2023
- Notable Start date: Jul 2019 to Oct 2019v13
- Notable Start date: Apr 2019 to Jul 2019v12
- Notable Start date: Feb 2019 to Apr 2019v11
- Minor Start date: Jan 2019 to Feb 2019v10
- Notable Start date: Nov 1, 2018 to Jan 2019
- Eligibility criteria shortened, about 39 words
- Study sites: 1 to 3
- Collaborators: 2 to 3
- Notable Start date: Aug 20, 2018 to Nov 1, 2018v8
Notable Phase: Phase 3 to Phase 2v7 Show 4 more changesShow less
- Start date: Jun 2018 to Aug 20, 2018
- Enrollment target: 160 to 162
- Study description revised
- Study title expanded, about 4 words
- Notable Start date: Jan 2018 to Jun 2018
- Collaborators revised (2)
- Notable Start date: Nov 1, 2017 to Jan 2018v5
- Notable Primary completion date: Jan 2021 to Jan 1, 2022
- Start date: Nov 2016 to Nov 1, 2017
- Study completion date: Jan 2022 to Jan 1, 2023
- Notable Eligibility criteria expanded, about 18 words
- Primary endpoint revised
- Secondary endpoints: details revised at 1 of 4 entries
- Notable Primary endpoint revised
- Secondary endpoints: 3 to 4
- Study description shortened, about 1,839 words
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Subjects randomized to receive Folinic Acid will take Liquid levo-leucovorin via oral route. The target dose is 1 mg/kg/day with a maximum of 25 mg/day, divided in two daily doses. A two- to four-week supply of 15 ml vials will be dispensed in line with the visit schedule. With the exception of children in the lowest weight group (≥ 15 - \< 20 kg) from days 1-14, parents will administer the prescribed dose twice a day at the same time each day.
Subjects randomized to receive placebo will take placebo twice a day (Exception: children in the lowest weight group ( ≥ 15 - \< 20 kg) will start once a day for Days1-13). The pattern of dose escalation will be the same as the active compound. After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
Drugs: Folinic Acid
Other: Placebo
Sites
4 sites in 1 country